title: Pharmacology and metabolism of voriconazole and Posaconazole in the treatment of invasive aspergillosis: review of the literature.
abstract: Invasive fungal infections, predominantly aspergillosis and candidiasis, are among the most important causes of morbidity and mortality in immunocompromised patients. Primarily, patients with acute leukemia undergoing myelosuppressive chemotherapy and allogeneic stem cell transplant recipients are affected. Up to 60% of patients with invasive aspergillosis, the most common invasive mycosis among patients with hematologic malignancies, may still die of their infection, once it has become clinically overt. The spectrum of antifungal agents for clinical use now has expanded over the past ten years and includes the novel class of the echinocandins and two newer generation triazoles with an extended spectrum of activity against a wide range of fungal pathogens. This review will address pharmacological characteristics of the two broad-spectrum antifungal azoles, voriconazole and Posaconazole, which are important for their proper use in clinical practice.
authors.affiliation: Hematology and Oncology Specialized Practice, Weilheim, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Sandherr
authors.forename: G
authors.initials: G
authors.lastname: Maschmeyer
mesh_terms: D000935:Antifungal Agents / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use; D004347:Drug Interactions; D006801:Humans; D055744:Invasive Pulmonary Aspergillosis / Q000188:drug therapy*; D011743:Pyrimidines / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use; D014230:Triazoles / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use; D065819:Voriconazole
chemical_list: D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; C101425:posaconazole; D065819:Voriconazole